Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6396086 | 1.00 | PTGS1 (0.53) | PTGS1LMNAMAPK1RXRARXRB | |
| SCHEMBL6396089 | 1.00 | PTGS1 (0.53) | PTGS1LMNAMAPK1RXRARXRB | |
| SCHEMBL6400603 | 0.84 | L3MBTL1 (0.58) | PTGS1LMNAMAPK1BLMNPSR1 | |
| SCHEMBL1416702 | 0.84 | PTGS1 (0.73) | PTGS1LMNAMAPK1RXRARXRB | |
| SCHEMBL503788 | 0.84 | L3MBTL1 (0.58) | PTGS1LMNAMAPK1BLMNPSR1 | |
| SCHEMBL503789 | 0.84 | L3MBTL1 (0.58) | PTGS1LMNAMAPK1BLMNPSR1 | |
| SCHEMBL6055421 | 0.82 | RXRA (0.47) | PTGS1RXRARXRBALDH1A1ACHE | |
| SCHEMBL21501376 | 0.81 | AKR1C3 (0.55) | PTGS1LMNAALDH1A1BLMNPSR1 | |
| SCHEMBL8589033 | 0.81 | PTGS1 (0.51) | PTGS1LMNARXRARXRBALDH1A1 | |
| SCHEMBL5746015 | 0.81 | PTGS1 (0.51) | PTGS1LMNARXRARXRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921758-B2 | Amino acid derivatives | ASTRAZENECA AB (SE) | 2005-07-26 | — | — | US | disclosed |
| US-20040087647-A1 | NEW AMINO ACID DERIVATIVES | ASTRAZENECA AB | 2004-05-06 | — | — | US | disclosed |
| US-6617320-B2 | Protease inhibitor; anticoagulants | ASTRAZENECA AB (SE) | 2003-09-09 | — | — | US | disclosed |
| EP-0836615-B1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | ASTRAZENECA AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| US-20020042396-A1 | Amino acid derivatives | ASTRA AB | 2002-04-11 | — | — | US | disclosed |
| US-6051568-A | Thrombin inhibitors, their preparation and use | ASTRA AKTIEBOLAG (SE) | 2000-04-18 | — | — | US | disclosed |
| US-5773620-A | Quaternary ammonium salts of aromatic amine compounds, their preparation and pharmaceutical compositions in which they are present | ELF SANOFI (FR) | 1998-06-30 | — | — | US | disclosed |
| US-5770735-A | Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions in which they are present | ELF SANOFI (FR) | 1998-06-23 | — | — | US | disclosed |
| EP-0836615-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | Astra Aktiebolag (SE) | 1998-04-22 | — | — | EP | disclosed |
| US-5674881-A | NEUROKININ RECEPTOR ANTAGONISTS | ELF SANOFI (FR) | 1997-10-07 | — | — | US | disclosed |
| US-5625060-A | Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions on which they are present | Sanofi, Elf (FR) | 1997-04-29 | — | — | US | disclosed |
| WO-1997002284-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | ASTRA AKTIEBOLAG (SE) | 1997-01-23 | — | — | WO | disclosed |
| US-5340822-A | Substance P, neurokinin antagonists | ELF SANOFI (FR) | 1994-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042396-A1 | Amino acid derivatives | F2, SERPINC1, ARGLU1 | PTGS1 441/4885LMNA 3361/4885MAPK1 1223/4885 |
| US-20040087647-A1 | NEW AMINO ACID DERIVATIVES | F2, ANPEP, PEPD | PTGS1 366/4885LMNA 2654/4885MAPK1 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.